Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

FASgen achieves significant milestone in cancer drug program

Oct. 4, 2007

Phase II studies show activity of SNS-595 in lung cancer

Oct. 4, 2007

Primary endpoint not reached in phase IIb trial of ANX-510

Oct. 4, 2007

Oncolytics Biotech reports positive interim data from combination Reolysin/radiation trial

Oct. 3, 2007

Taxotere receives FDA approval for expanded SCCHN indication

Oct. 3, 2007

RDEA-119 enters human clinical trials in advanced cancer patients

Oct. 3, 2007

Positive results for Diffusion's phase I safety trial of TSC

Oct. 3, 2007

BioLineRx in-licenses novel peptide for cancer

Oct. 3, 2007

Preclinical efficacy, pharmacokinetics and safety of the ETB agonist SPI-1620

Oct. 3, 2007

Recent patents impart new therapeutic agents for cancer

Oct. 2, 2007

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...